Payment overview · 2025
General Payments
$479.04
28 reported records · 12 companies
Healthcare provider profile · identity verified
Kevin E Moore, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BARDSTOWN, KY · NPI 1740270016
Verified facts
What the public records show
CMS Open Payments records show Kevin E Moore, M.D. received $479.04 in general payments during 2025 across 28 reported records.
ABBVIE INC. accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $103.24 | 21.6% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $62.70 | 13.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.37 | 10.7% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.94 | 10.6% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $47.35 | 9.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $42.87 | 8.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.04 | 5.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.51 | 4.5% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $21.40 | 4.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.49 | 3.6% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17.47 | 3.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.66 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $479.04 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $55.66 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $47.58 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $47.58 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $47.35 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $42.87 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $42.87 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $35.73 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.06 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.06 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $34.07 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $34.07 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $34.07 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $28.63 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.04 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 98 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 64 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
60 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
64 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
98 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
209 | 47 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 654 | 181 |
| Amlodipine Besylate | Amlodipine Besylate | 514 | 148 |
| Levothyroxine Sodium | Levothyroxine Sodium | 448 | 104 |
| Metoprolol Succinate | Metoprolol Succinate | 370 | 108 |
| Lisinopril | Lisinopril | 355 | 97 |
| Omeprazole | Omeprazole | 346 | 86 |
| Gabapentin | Gabapentin | 322 | 64 |
| Losartan Potassium | Losartan Potassium | 259 | 74 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 248 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 246 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 226 | 66 |
| Eliquis | Apixaban | 209 | 47 |
| Metformin Hcl Er | Metformin Hcl | 203 | 54 |
| Furosemide | Furosemide | 197 | 66 |
| Metformin Hcl | Metformin Hcl | 196 | 61 |
| Meloxicam | Meloxicam | 179 | 47 |
| Potassium Chloride | Potassium Chloride | 169 | 43 |
| Sertraline Hcl | Sertraline Hcl | 168 | 45 |
| Montelukast Sodium | Montelukast Sodium | 157 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 154 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 154 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 45 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 134 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 127 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 36 |
| Clonazepam | Clonazepam | 121 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 38 |
| Baclofen | Baclofen | 110 | 25 |
| Ozempic | Semaglutide | 98 | 24 |
| Alprazolam | Alprazolam | 97 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 95 | 21 |
| Trazodone Hcl | Trazodone Hcl | 91 | 25 |
| Glimepiride | Glimepiride | 87 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 84 | 23 |
| Carvedilol | Carvedilol | 82 | 25 |
| Allopurinol | Allopurinol | 78 | 20 |
| Buspirone Hcl | Buspirone Hcl | 77 | 19 |
| Famotidine | Famotidine | 77 | 22 |
| Simvastatin | Simvastatin | 76 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 17 |
| Jardiance | Empagliflozin | 69 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 67 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | 13 |
| Bupropion Xl | Bupropion Hcl | 63 | 17 |
| Prednisone | Prednisone | 63 | 38 |
| Pregabalin | Pregabalin | 63 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 63 | 14 |
| Atenolol | Atenolol | 61 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 16 |
| Bumetanide | Bumetanide | 60 | 17 |
| Synthroid | Levothyroxine Sodium | 60 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 57 | 15 |
| Tramadol Hcl | Tramadol Hcl | 57 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 15 |
| Alendronate Sodium | Alendronate Sodium | 44 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | 12 |
| Lorazepam | Lorazepam | 38 | 11 |
| Trulicity | Dulaglutide | 38 | suppressed |
| Finasteride | Finasteride | 37 | suppressed |
| Valsartan | Valsartan | 37 | suppressed |
| Chlorthalidone | Chlorthalidone | 36 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 32 |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 35 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 27 |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 24 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 21 | suppressed |
| Constulose | Lactulose | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 17 |
| Estradiol | Estradiol | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 11 |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 14 |
| Torsemide | Torsemide | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Naproxen | Naproxen | 16 | 13 |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 12 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $479.04 · 28 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, APTIMA, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Kerendia, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VRAYLAR, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error